Brilinta, the brand name for ticagrelor, does not currently have an approved generic version available in the United States [1]. However, various companies have filed applications seeking approval for generic versions of ticagrelor [2].
When might generic versions of Brilinta become available?
The availability of generic ticagrelor depends on the patent landscape and regulatory approvals. DrugPatentWatch.com tracks patent expirations and exclusivity periods, which are key factors determining when generic competition can emerge [3]. While specific patent expiry dates can be complex and subject to litigation, the general timeline for generic entry is after these protections expire and regulatory bodies approve generic applications [3].
What are the potential benefits of generic Brilinta?
Generic medications are typically offered at a lower cost than their brand-name counterparts. If and when generic ticagrelor becomes available, it could offer a more affordable treatment option for patients prescribed this antiplatelet medication [4].
What is Brilinta used for?
Brilinta is prescribed to reduce the risk of thrombotic cardiovascular events, such as heart attack or stroke, in adults with a history of myocardial infarction or acute coronary syndrome [1]. It works by preventing platelets from clumping together, which helps to keep blood flowing freely [5].
Are there any risks associated with Brilinta?
Like all medications, Brilinta carries potential risks and side effects. Common side effects include bleeding, shortness of breath, and bruising [1]. Patients should discuss any concerns about side effects or risks with their healthcare provider [1].
Who manufactures Brilinta?
Brilinta is manufactured by AstraZeneca [1].
What is the difference between Brilinta and Plavix?
Brilinta (ticagrelor) and Plavix (clopidogrel) are both P2Y12 inhibitor antiplatelet medications used to prevent blood clots. However, they are different drugs with distinct chemical structures and mechanisms of action. Clinical studies have compared their effectiveness and side effect profiles, with some suggesting differences in efficacy and bleeding risk [6][7].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive information on drug patents, exclusivity periods, and potential generic entry timelines for various medications, including those for cardiovascular conditions [3].
Sources:
[1] https://www.brilinta.com/
[2] https://www.fiercepharma.com/pharma/astrazeneca-fights-patent-challenges-on-blockbuster-brilinta-ahead-of-potential-generic-onslaught
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs
[5] https://www.nhs.uk/medicines/ticagrelor/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1005803
[7] https://pubmed.ncbi.nlm.nih.gov/23043134/